Related Experiment Video
Updated: Jan 16, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Public Health System Funding for isCGM Reduces Socioeconomic Disparities in Type 2 Diabetes Control: A Cohort Study
Fernando Sebastian-Valles1, Jessica Jimenez-Diaz2, Carolina Sager-La Ganga1
1Department of Endocrinology and Nutrition, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
Abstract:
Objective: The objective of this study is to assess whether the provision of free intermittently scanned continuous glucose monitoring (isCGM) systems can reduce socioeconomic disparities in glycemic control among individuals with Type 2 diabetes mellitus (T2D) treated with multiple daily insulin injections. Methods: This is a cohort study involving 402 T2D patients from three hospitals, all of whom initiated isCGM use as part of routine clinical practice. The isCGM systems were provided free of charge through public healthcare funding, with no out-of-pocket cost to the patients. Glycated hemoglobin (HbA1c) levels were recorded before and after at least 3 months of sensor use. Socioeconomic status (SES) was determined based on the average annual net income per person within the census tract for each patient. Results: Prior to the sensor placement, the mean HbA1c was 8.9% for patients in the lowest SES quartile and 8.2% for those in the highest quartile (p = 0.009). Following isCGM implementation, significant HbA1c reductions were observed across all SES groups, with decreases of 1.0% in the lowest quartile and 0.6% in the highest (p < 0.001). Postintervention differences in HbA1c between SES quartiles were not statistically significant (p = 0.509). Conclusion: Public funding of isCGM systems is associated with a significant improvement in glycemic control and contributes to the reduction of pre-existing socioeconomic disparities in healthcare among T2D patients treated with insulin.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Bias in Epidemiological Studies
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Methods Of Healthcare Delivery System
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

